Abstracts tagged "prevention"

Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Luciana Parente Costa Seguro¹, Andrea Negrini², Sandra G Pasoto³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro³, Eduardo Borba¹, Emily Figueiredo Neves Yuki⁵, Artur Sartori², Danieli Andrade⁶, Thiago Freitas⁷, Henrique Giardini⁷, Clovis Artur Silva⁸ and Eloisa Bonfa¹, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
Abstract Number: 1674 • ACR Convergence 2025
A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
Kevin Deane¹, Christopher Striebich², Marie Feser³, James O'Dell⁴, Judith James⁵, Jeffrey Sparks⁶, John Davis⁷, Jonathan Graf⁸, Maureen McMahon⁹, Elizabeth Solow¹⁰, Lindsy Forbess¹¹, Athan Tiliakos¹², Elena Schiopu¹³, David Fox¹⁴, Maria I. ("Maio") Danila¹⁵, Diane Horowitz¹⁶, Jonathan Kay¹⁷, Colin Strickland³, Joel Guthridge⁵, Cristina Arriens⁵, Jennifer Grossman¹⁸, Kristen Demoruelle¹⁹, Elizabeth Bemis³, Ashley Frazer-Abel³, Chelsie Fleischer²⁰, Ted Mikuls⁴, Melissa Greenleaf²¹, Kate York²², Sarah Walker²³, Lynette Keyes-Elstein²³, Margie Byron²³, Janel Fedler²⁴, Ellen Goldmuntz²⁵ and V. Michael Holers²⁶, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Mayo Clinic, Rochester, MN, ⁸UCSF, San Francisco, CA, ⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Emory University, Roswell, GA, ¹³Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴University of Michigan, Dexter, MI, ¹⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁶Northwell Health, Jericho, NY, ¹⁷UMass Chan Medical School, Worcester, MA, ¹⁸UCLA, Sherman Oaks, CA, ¹⁹University of Colorado Anschutz Medical Campus, Golden, CO, ²⁰University of Colorado Denver, Aurora, CO, ²¹National Institutes of Health, Rockville, MD, ²²Rho, Inc, Durham, NC, ²³Rho, Inc., Durham, NC, ²⁴Rho, Inc., Salem, IA, ²⁵NIAID/ NIH, Washington, DC, ²⁶University of Colorado, Denver, CO
Background/Purpose: Individuals with elevations of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies are at-risk for rheumatoid arthritis (RA). Identification of interventions to prevent RA in anti-CCP-positive…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…
Abstract Number: 0382 • ACR Convergence 2025
Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
Sandhya shri Kannayiram¹, Amaya Smole², Lucy Masto³, Yongjay Kim⁴, Neha Nagpal¹, Naiva Manuela Piatchou Donfack¹, Deanna Jannat-Khah¹, Lisa Mandl¹, Sarah Lieber¹, Caroline Siegel¹, Michael Lockshin⁵, Lisa Sammaritano¹ and Medha Barbhaiya¹, ¹HOSPITAL FOR SPECIAL SURGERY, New york, NY, ²Hospital for Special Surgery, Brooklyn, NY, ³Hospital for Special Surgery, San Francisco, CA, ⁴Hospital for Special Surgery, Englewood Cliffs, NJ, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Timely preventative health screenings in women with systemic rheumatic diseases (SRDs), especially those with other chronic conditions or who are on immunosuppressive therapy, may…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 0366 • ACR Convergence 2025
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
Fernanda M. Garcia-Garcia¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Gabriel P. Castro-Cruz³, Carlos I. Estrada-Anguiano³, Jennifer Garcia-Bravo³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado¹ and Janett C. Riega-Torres⁴, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health conditions are frequent in patients with rheumatic diseases and can impact daily function and quality of life. Factors such as chronic inflammation…
Abstract Number: 2653 • ACR Convergence 2025
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Ana Paula Luppino-Assad¹, Renata P Mello², Ana C Medeiros-Ribeiro³, Nadia E Aikawa⁴, Sandra G Pasoto³, Leonard V Kupa⁵, Renata Miossi⁶, Percival D Sampaio-Barros⁶, Eduardo Borba⁷, Eloisa Bonfa⁷ and Clovis Artur Silva⁸, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ⁷Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Systemic sclerosis (SSc) patients are at higher risk of herpes zoster (HZ) due to underlying immune dysregulation and immunosuppressive therapies. Vaccination is a key…
Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Kristina Ciaglia¹ and Magan Fosso², ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…
Abstract Number: 0211 • ACR Convergence 2025
Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
Alexandra Do¹, Lisa Matsumoto¹, Cherish Wilson², Gary Tarasovsky³, gabriela Schmajuk⁴ and Jennifer Barton⁵, ¹Oregon Health and Science University, Portland, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
Abstract Number: 2613 • ACR Convergence 2025
Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
Giulia Corte¹, Koray Tascilar², armin Atzinger³, Alp Temiz², Melek Yalcin Mutlu⁴, Rita Noversa de Sousa⁵, Maria Gabriella Raimondo⁶, Andreas Ramming⁷, Sara Bayat², Michael Sticherling⁸, Torsten Kuwert⁹, Christian Schmidkonz⁹, Georg Schett¹⁰ and Filippo Fagni¹¹, ¹- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, erlangen, ⁵Department of Internal Medicine ³, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ⁶Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany
Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 2608 • ACR Convergence 2025
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Maria Dons¹, Charlotte Näslund-Koch², Morten Sengeløv³, Sofie Bøgh-Sørensen³, Kristoffer Skaarup³, Marianne Bengtson Løvendorf⁴, Filip Davidovski³, Anne Marie Reimer Jensen³, Brittany Weber⁵, Lise Lotte Gluud⁶, Claus Zachariae², Lone Skov² and Tor Biering-Sørensen³, ¹Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ²Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
Abstract Number: 1260 • ACR Convergence 2025
Increasing Zoster Vaccination Rates in Immunosuppressed Veterans at the North Texas VA Medical Center Rheumatology Clinic
Benjamin Gardner¹, Ankitha Lingamaneni², Isabel Penabad³, Jiby Mathew⁴, Una Makris⁵, Rashmi Arora⁶, Swathi Reddy⁷ and Nagendra Pokala⁸, ¹UTSW, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴Veteran's Affairs, Rowlett, TX, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶VA north texas health centre Dallas, Dallas, TX, ⁷UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX, ⁸Veterans Affairs North Texas Healthcare System, Dallas, TX
Background/Purpose: Shingles is a painful cutaneous eruption due to the reactivation of latent Varicella zoster virus. Immunocompromised adults, due to a medical condition or immunosuppressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].